← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 32.3% to $507.4M, while Net income decreased 28.2% to ($187.7M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $507.4MWatch
- Profitability — Net income ($187.7M)Watch
- Cash generation — Free cash flow ($22.5M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality greyWatch
- Insiders — 0 buys; 21 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
GLAUKOS Corp: We have three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent , the iStent inject W , and the iStent infinite , collectively referred to as the " iStent family of products." The iStent, and the iStent inject W are micro-bypass stents designed to treat mild-to-moderate open angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Where the revenue comes from
Fiscal 2025, as GLAUKOS Corp reports it. History and quarterly detail are in the app.
- Glaucoma$421.1M
- Corneal Health$86.4M
Latest filings
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-29
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about GLAUKOS Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.